Clinical trials: Soft-tissue Sarcoma, open to volunteers
Rhabdomyosarcoma, Pediatric Cancer
Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen
This study comprises both Phase I and Phase II research. This phase focuses on safety, tolerability, and pharmacokinetics using a "3+3" dose escalation design with three dose groups: 1 mg/kg, 3 mg/kg, and 6 mg/kg.
- Trial name
- NCT06456892
- Testing
- Pucotenlimab
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Sun Yat-sen University
Neuroblastoma, Rhabdomyosarcoma
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors
- Trial name
- NCT06625190
- Testing
- Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Florida
Desmoplastic Small Round Cell Tumor, Osteosarcoma
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
This phase I/II trial studies the effects of trastuzumab deruxtecan (DS-8201a) in treating patients with osteosarcoma, Wilms tumor (WT) or desmoplastic small round cell tumor (DSRCT) that is newly diagnosed or has come back after…
- Conditions
- Desmoplastic Small Round Cell Tumor, Osteosarcoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Kidney Wilms Tumor
- Trial name
- NCT04616560
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 32 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Osteosarcoma
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
To evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.
- Trial name
- NCT06714383
- Testing
- Trilaciclib, Pirarubicin, Lobaplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Recurrent Solid Tumor, Recurrent Ewing Sarcoma
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away).
- Conditions
- Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor
- Trial name
- NCT04901702
- Testing
- Onivyde, Talazoparib, Temozolomide
- Where
- 10 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- St. Jude Children's Research Hospital
Malignant Peripheral Nerve Sheath Tumors, MPNST
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor
People who have a cancer called MPNST, or Malignant Peripheral Nerve Sheath Tumor, may be eligible for this study. The purpose of this study is to see if a new medicine called BMS-986504 may work better than other available…
- Trial name
- NCT07549022
- Testing
- BMS-986504
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Ankit Mangla, MD
Sarcoma, Childhood Osteosarcoma
Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas
RAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy.
- Conditions
- Sarcoma, Childhood Osteosarcoma, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma
- Trial name
- NCT07222735
- Testing
- Fludarabine, Cyclophosphamide, B7-H3-CAR T Cells
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- St. Jude Children's Research Hospital
Osteosarcoma Recurrent, Osteosarcoma in Children
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitabine in patients with relapsed or refractory osteosarcoma (OS).
- Conditions
- Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
- Trial name
- NCT07144254
- Testing
- Tegavivint, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Neuroblastoma, Sarcoma
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon…
- Trial name
- NCT05135975
- Testing
- Cabozantinib
- Where
- 6 sites in United States
- Volunteers
- 86 people
- Sponsor
- Nationwide Children's Hospital
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
There is a significant unmet medical need for effective therapies for pediatric relapsed/refractory solid tumors. EGFR is highly and stably expressed in multiple pediatric solid tumor subtypes, and adult Phase I data of Becotatug…
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
- Trial name
- MRG003 (NCT07584499)
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Relapsed / Refractory Osteosarcoma
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma.
- Trial name
- NCT07357519
- Testing
- LNTH2403 Phase 1 dose, Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Lantheus Medical Imaging
Osteosarcoma
Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma
Prospective, open, interventional, randomized, non-commercial trial
- Trial name
- Dragonfly (NCT07787429)
- Testing
- Mifamurtide, Sorafenib
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Anna Raciborska
Pediatric Osteosarcoma
Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma
The purpose of this study is to assess the safety, feasibility, and effectiveness of a consolidative B7-H3 CAR T cell therapy in patients with newly diagnosed high-risk osteosarcoma who have undergone upfront standard…
- Trial name
- NCT07428993
- Testing
- Cyclophosphamide, Fludarabine, Mesna
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- St. Jude Children's Research Hospital
Refractory Solid Tumors, Relapsed Solid Tumors
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vincristine and temozolomide (phase 1B).
- Conditions
- Refractory Solid Tumors, Relapsed Solid Tumors, Relapsed Neuroblastoma, Refractory Neuroblastoma
- Trial name
- PEEL-224 (NCT06721689)
- Testing
- PEEL-224, Vincristine, Temozolomide (TMZ)
- Where
- 7 sites in United States
- Volunteers
- 59 people
- Sponsor
- Theodore Laetsch
Malignant Peripheral Nerve Sheath Tumors
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or…
- Trial name
- NCT03141021
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 1,050 people
- Sponsor
- Washington University School of Medicine
Sarcoma, Pediatric Brain Tumors
Pediatric Radiation Therapy Registry
The Johns Hopkins Pediatric Radiation Oncology Program is creating a registry that will capture the full 3D radiation dosimetry delivered to its pediatric patients to manage the quality of care provided, as well as to examine the…
- Trial name
- NCT07129317
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HIV, Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
New Approaches for the Diagnosis of Lymphoma and Multicentric Castleman Disease
Persons living with HIV (PLWH) in sub-Saharan Africa (SSA), lymphadenopathy often portends one of a number of life-threatening diseases including tuberculosis, lymphoma, and multicentric Castleman disease (MCD).
- Conditions
- HIV, Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT07793006
- Testing
- Lymph Node or Core Needle Biopsy, Fine Needle Aspiration, Tiny Isothermal Nucleic acid Amplification System (TINY)
- Where
- Malawi
- Volunteers
- 500 people
- Sponsor
- Indiana University
Ewing Sarcoma, Osteosarcoma
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory sarcomas.
- Conditions
- Ewing Sarcoma, Osteosarcoma, Sarcomas
- Trial name
- NCT06156410
- Testing
- Cabozantinib
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Philadelphia
Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
This is a prospective, single-center, single-arm interventional trial conducted at Tianjin Medical University Cancer Institute and Hospital.
- Trial name
- NCT07444918
- Testing
- Liposomal Irinotecan, Vincristine, Temozolomide, and Optional Anlotinib
- Volunteers
- 33 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Ewing Sarcoma
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric…
- Trial name
- NCT07297979
- Testing
- Xaluritamig
- Where
- 13 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Amgen